gankyrin Antibody (A-8): sc-166376

gankyrin Antibody (A-8) is a mouse monoclonal IgG1 antibody that detects gankyrin in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Gankyrin is a crucial protein associated with hepatocellular carcinoma, playing a significant role in regulating protein-protein interactions that are vital for cell cycle control and protein degradation. Gankyrin is primarily located in the cytoplasm, where gankyrin interacts with key regulatory proteins such as retinoblastoma protein (Rb) and cyclin-dependent kinase 4 (Cdk4), which are essential for cell cycle progression. This localization enables gankyrin to effectively modulate the cell cycle and influence cellular responses to stress and growth signals. Additionally, gankyrin′s interaction with the 26S proteasome facilitates the degradation of specific proteins, thereby maintaining cellular homeostasis. Gankyrin also interacts with MAGE-A4, a protein that has been implicated in the suppression of anchorage-independent growth in cells overexpressing gankyrin, highlighting gankyrin′s potential as a target for immunotherapy in hepatocellular carcinoma. anti-gankyrin antibody (A-8) versatility in various applications makes anti-gankyrin antibody (A-8) an invaluable tool for researchers studying cancer biology and cell cycle regulation.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

gankyrin Antibody (A-8) References:

1. Gankyrin-mediated dedifferentiation facilitates the tumorigenicity of rat hepatocytes and hepatoma cells.  |  Sun, W., et al. 2011. Hepatology. 54: 1259-72. PMID: 21735473
2. Gankyrin facilitates follicle-stimulating hormone-driven ovarian cancer cell proliferation through the PI3K/AKT/HIF-1α/cyclin D1 pathway.  |  Chen, J., et al. 2016. Oncogene. 35: 2506-17. PMID: 26364616
3. Clinicopathologic features and prognostic implications of Gankyrin protein expression in non-small cell lung cancer.  |  Wang, WP., et al. 2015. Pathol Res Pract. 211: 939-47. PMID: 26554593
4. Gankyrin has an antioxidative role through the feedback regulation of Nrf2 in hepatocellular carcinoma.  |  Yang, C., et al. 2016. J Exp Med. 213: 859-75. PMID: 27091842
5. Gankyrin promotes the proliferation of gastric cancer and is associated with chemosensitivity.  |  Zeng, YC., et al. 2017. Tumour Biol. 39: 1010428317704820. PMID: 28653901
6. Gankyrin induces STAT3 activation in tumor microenvironment and sorafenib resistance in hepatocellular carcinoma.  |  Sakurai, T., et al. 2017. Cancer Sci. 108: 1996-2003. PMID: 28777492
7. Gankyrin Contributes to Tumorigenesis and Chemoresistance in Sporadic Colorectal Cancer.  |  Sakurai, T., et al. 2019. Digestion. 100: 192-200. PMID: 30513515
8. Exploring gankyrin's role in cancer development and its potential as a therapeutic target.  |  Kanabar, D. and Muth, A. 2020. Future Med Chem. 12: 1603-1606. PMID: 32892644
9. Gankyrin as Potential Biomarker for Colorectal Cancer With Occult Liver Metastases.  |  Wang, C., et al. 2021. Front Oncol. 11: 656852. PMID: 34395241
10. A druggable pocket on PSMD10Gankyrin that can accommodate an interface peptide and doxorubicin.  |  M G, MS., et al. 2022. Eur J Pharmacol. 915: 174718. PMID: 34953804

The preferred gankyrin antibody is gankyrin Antibody (3A6C2): sc-101498.